Preclinical Models for Functional Precision Lung Cancer Research
Cancers · 25.12.2024 · 17 (1) · 22
DOI: 10.3390/cancers17010022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.12.2024. Verfasst von Jie-Zeng Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis C…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, ORD VA, Merit Award.
Abstract (Originalsprache)
Patient-centered precision oncology strives to deliver individualized cancer care. In lung cancer, preclinical models and technological innovations have become critical in advancing this approach. Preclinical models enable deeper insights into tumor biology and enhance the selection of appropriate systemic therapies across chemotherapy, targeted therapies, immunotherapies, antibody–drug conjugates, and emerging investigational treatments. While traditional human lung cancer cell lines offer a basic framework for cancer research, they often lack the tumor heterogeneity and intricate tumor–stromal interactions necessary to accurately predict patient-specific clinical outcomes. Patient-derived xenografts (PDXs), however, retain the original tumor’s histopathology and genetic features, providing a more reliable model for predicting responses to systemic therapeutics, especially molecularly targeted therapies. For studying immunotherapies and antibody–drug conjugates, humanized PDX mouse models, syngeneic mouse models, and genetically engineered mouse models (GEMMs) are increasingly utilized. Despite their value, these in vivo models are costly, labor-intensive, and time-consuming. Recently, patient-derived lung cancer organoids (LCOs) have emerged as a promising in vitro tool for functional precision oncology studies. These LCOs demonstrate high success rates in growth and maintenance, accurately represent the histology and genomics of the original tumors and exhibit strong correlations with clinical treatment responses. Further supported by advancements in imaging, spatial and single-cell transcriptomics, proteomics, and artificial intelligence, these preclinical models are reshaping the landscape of drug development and functional precision lung cancer research. This integrated approach holds the potential to deliver increasingly accurate, personalized treatment strategies, ultimately enhancing patient outcomes in lung cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA.
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
- Medical Service, Hematology/Oncology, Veterans Affairs Northern California Health Care System, Mather, CA 10535, USA.
ORCID-Profile: Jie-Zeng Yu, Weijie Ma, Ruqiang Liang, Tianhong Li
Förderung
- BLRD VA
- ORD VA
- Merit Award
- Office of Research & Development (ORD) of the Department of Veterans Affairs (VA), University of California Lung Cancer Consortium (UCLCC)
- Personalized Cancer Therapy Gift Fund
Zitieren
APA
Yu, J. Z., Kiss, Z., Ma, W., Liang, R., & Li, T. (2024). Preclinical Models for Functional Precision Lung Cancer Research. Cancers, 17(1), 22. https://doi.org/10.3390/cancers17010022
Vancouver
Yu JZ, Kiss Z, Ma W, Liang R, Li T. Preclinical Models for Functional Precision Lung Cancer Research. Cancers. 2024;17(1):22. doi:10.3390/cancers17010022
BibTeX
@article{Yu2024,
author = {Yu, Jie-Zeng and Kiss, Zsofia and Ma, Weijie and Liang, Ruqiang and Li, Tianhong},
title = {Preclinical Models for Functional Precision Lung Cancer Research},
journal = {Cancers},
year = {2024},
volume = {17},
number = {1},
pages = {22},
doi = {10.3390/cancers17010022}
}
EUVIMED